AU2008334543B2 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2008334543B2
AU2008334543B2 AU2008334543A AU2008334543A AU2008334543B2 AU 2008334543 B2 AU2008334543 B2 AU 2008334543B2 AU 2008334543 A AU2008334543 A AU 2008334543A AU 2008334543 A AU2008334543 A AU 2008334543A AU 2008334543 B2 AU2008334543 B2 AU 2008334543B2
Authority
AU
Australia
Prior art keywords
drug substance
micronised
process according
drug
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008334543A
Other languages
English (en)
Other versions
AU2008334543A1 (en
Inventor
Michael Juhnke
Gerhard Muhrer
Norbert Rasenack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39472711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008334543(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2008334543A1 publication Critical patent/AU2008334543A1/en
Application granted granted Critical
Publication of AU2008334543B2 publication Critical patent/AU2008334543B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2008334543A 2007-12-13 2008-12-11 Organic compounds Ceased AU2008334543B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123164 2007-12-13
EP07123164.1 2007-12-13
PCT/EP2008/067359 WO2009074662A2 (en) 2007-12-13 2008-12-11 Organic compounds

Publications (2)

Publication Number Publication Date
AU2008334543A1 AU2008334543A1 (en) 2009-06-18
AU2008334543B2 true AU2008334543B2 (en) 2011-07-28

Family

ID=39472711

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008334543A Ceased AU2008334543B2 (en) 2007-12-13 2008-12-11 Organic compounds

Country Status (13)

Country Link
US (1) US20100247658A1 (OSRAM)
EP (1) EP2234595B1 (OSRAM)
JP (1) JP2011506399A (OSRAM)
KR (1) KR20100099281A (OSRAM)
CN (1) CN101896162B (OSRAM)
AU (1) AU2008334543B2 (OSRAM)
BR (1) BRPI0821186A2 (OSRAM)
CA (1) CA2708083C (OSRAM)
ES (1) ES2396471T3 (OSRAM)
PL (1) PL2234595T3 (OSRAM)
PT (1) PT2234595E (OSRAM)
RU (1) RU2482838C2 (OSRAM)
WO (1) WO2009074662A2 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010253770B9 (en) * 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10888500B2 (en) 2016-07-29 2021-01-12 Inke, S.A. Particle size stabilization process
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
IT202300022716A1 (it) 2023-10-30 2025-04-30 Ind Chimica Srl Processo di condizionamento di fluticasone furoato micronizzato

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076575A2 (en) * 2000-04-07 2001-10-18 Arakis Ltd. The treatment of respiratory diseases
US20020173536A1 (en) * 1996-11-11 2002-11-21 Christian Noe And Ernst Mutschler Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
EP1834624A1 (en) * 2005-01-07 2007-09-19 Eisai R&D Management Co., Ltd. Medicinal composition and process for producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
PT2283817T (pt) * 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
WO2005046655A1 (en) * 2003-11-04 2005-05-26 Shire Laboratories, Inc. Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
KR101179393B1 (ko) * 2004-03-23 2012-09-07 노파르티스 아게 제약 조성물
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173536A1 (en) * 1996-11-11 2002-11-21 Christian Noe And Ernst Mutschler Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
WO2001076575A2 (en) * 2000-04-07 2001-10-18 Arakis Ltd. The treatment of respiratory diseases
EP1834624A1 (en) * 2005-01-07 2007-09-19 Eisai R&D Management Co., Ltd. Medicinal composition and process for producing the same

Also Published As

Publication number Publication date
WO2009074662A3 (en) 2009-09-24
EP2234595A2 (en) 2010-10-06
CA2708083C (en) 2016-06-28
ES2396471T3 (es) 2013-02-21
RU2482838C2 (ru) 2013-05-27
CN101896162B (zh) 2013-06-05
PT2234595E (pt) 2013-01-24
CN101896162A (zh) 2010-11-24
RU2010128246A (ru) 2012-01-20
CA2708083A1 (en) 2009-06-18
BRPI0821186A2 (pt) 2015-06-16
WO2009074662A2 (en) 2009-06-18
EP2234595B1 (en) 2012-11-28
AU2008334543A1 (en) 2009-06-18
JP2011506399A (ja) 2011-03-03
PL2234595T3 (pl) 2013-04-30
KR20100099281A (ko) 2010-09-10
US20100247658A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
CA2708083C (en) Organic compounds
US9050267B2 (en) Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
AU2008334547B2 (en) Organic compounds
SG186427A1 (en) Dry powder formulation comprising an antimuscarinic drug
US9889094B2 (en) Particle size reduction of an antimuscarinic compound
WO2012016889A2 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
CN113105453A (zh) 嘧啶并[6,1-a]异喹啉-4-酮化合物的盐
US20200155506A1 (en) Formulation comprising glycopyrrolate, method and apparatus
WO2021033081A1 (en) Stable aerosol composition for inhalation comprising glycopyrronium, formoterol and corticosteroid
HK40035236A (en) Formulation comprising glycopyrrolate, method and apparatus
HK1241279A1 (en) Formulation comprising glycopyrrolate, method and apparatus
HK1241279B (en) Formulation comprising glycopyrrolate, method and apparatus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired